-
Mashup Score: 33
Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care th…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
This study compares the race and ethnicity of reproductive-age females between states that implemented restrictive abortion policies after the Dobbs v Jackson Women’s Health Organization decision and states that did not.
Source: jamanetwork.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Le diagnostic à l'ère numérique : en faveur des vidéos personnelles // International League Against Epilepsy - 1 hour(s) ago
Epigraph Vol. 26 Issue 2, Spring 2024 Cite this article: Volkers N. Gotman J. Le diagnostic à l’ère numérique : en faveur des vidéos personnelles. Epigraph 2024; 26(2):57-61. L’homme à la clinique a eu deux épisodes ressemblant à des crises au cours de sa vie. Selim Benbadis, directeur du programme d’épilepsie de l’Université de Floride du Sud, et son résident conduisent une anamnèse et font un examen. Ils sont assez confiants que l’homme souffre de syncope. Plus tard, l’homme leur envoie une vidéo prise
Source: www.ilae.orgCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 0OncLive - Clinical Oncology News, Cancer Expert Insights - 1 hour(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Combination BrECADD Is Significantly More Effective Than BEACOPP for Classical Hodgkin Lymphoma, Study Finds - 1 hour(s) ago
The combination regimen of BrECADD for the treatment of advanced-stage classical Hodgkin lymphoma was found to be significantly more effective than a regimen of BEACOPP. BrECADD was associated with an…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0TED Patients Report Maintained Improvement 2 Years After Teprotumumab Infusions - Endocrine News - 1 hour(s) ago
Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly two years later, according to industry-supported research being presented Sunday at ENDO 2024 in Boston, Mass., and published in the journal Thyroid. “Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated….
Source: endocrinenews.endocrine.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 0Privacy remains an issue with several women’s health apps - 1 hour(s) ago
Inconsistent privacy policies and dodgy data collection in popular fertility and pregnancy tracking apps put women’s health information at risk.
Source: www.sciencenews.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 7
Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; …
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Young-Onset Dementia Tied to Preeclampsia - 1 hour(s) ago
Study of 2 million women in France identifies new association
Source: www.medpagetoday.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma - 1 hour(s) ago
Pan et al. demonstrate the safety, efficacy, and survival of TAEST16001 cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma. They show that TAEST16001 cell therapy is well tolerated and has promising anti-tumor activities for advanced soft tissue sarcoma expressing the NY-ESO-1 antigen.
Source: www.cell.comCategories: General Medicine News, General HCPsTweet
DREAMM-7: Among patients with relapsed myeloma, median PFS was about 3 years with a regimen including the anti-BCMA antibody–drug conjugate belantamab mafodotin, as compared with about 13 months with a regimen including an anti-CD38 antibody. https://t.co/Gc7WWMdXUm #ASCO24 https://t.co/39LTiEiWaf